Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Evolution Clinical Trials

Neither a doctor nor a teaching hospital

Research payments

$1,093,391

392 payments

Through program year 2025, Evolution Clinical Trials is reported as receiving $1,093,391 in research payments, across 392 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $710,132 294
2024 Research $104,754 24
2023 Research $94,181 21
2022 Research $146,122 43
2021 Research $38,201 10

Breakdown

Who paid Research payments · program years 2021–2025
  1. Boehringer Ingelheim International GmbH $533,676 251 payments
  2. Taro Pharmaceuticals USA, Inc. $253,719 72 payments
  3. Regeneron Pharmaceuticals, Inc. $176,774 44 payments
  4. Sun Pharmaceutical Industries Inc. $96,371 19 payments
  5. Chiesi USA, Inc. $32,851 6 payments
Studies the money was for Research payments · program years 2021–2025
  1. Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial $468,483 177 payments
  2. A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy And Safety of SCD-044 in the Treatment of Moderate to Severe Plaque Psoriasis $199,532 46 payments
  3. A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors $176,774 44 payments
  4. A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Atopic Dermatitis $112,357 35 payments
  5. A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis $60,444 59 payments
  6. Study $38,201 10 payments
  7. A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (Triton) $24,785 2 payments
  8. A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) $8,066 4 payments
  9. A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis $4,432 14 payments
  10. -Ph III MASH pivotal trials $317 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record